Oxford Biomedica plummets on test results

Shares in Oxford Biomedica slumped to a 52-week low after a disappointing set of test results for ProSavin, its treatment for Parkinson's disease.

Shares in Oxford Biomedica slumped to a 52-week low after a disappointing set of test results for ProSavin, its treatment for Parkinson's disease.

In clinical trials it appears that while higher doses of the drug initially improved symptoms for patients, after six months the benefits of higher dosages ceased to be statistically significant in comparison with normal dosages.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up
MoneyWeek

MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.